Key Points
- Director Shirley Weis sold 36,028 shares of Pediatrix Medical Group on May 13 at an average price of $23.75, for a total of about $855,665.
- The company beat quarterly earnings and revenue estimates, reporting EPS of $0.44 versus $0.37 expected and revenue of $476.2 million versus $465.83 million estimated.
- Analysts remain cautious overall: Pediatrix Medical Group has a consensus rating of “Hold” with an average price target of $22.50, even after some firms adjusted targets in the low-to-mid $20s.
Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) Director Shirley Weis sold 36,028 shares of the firm's stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Pediatrix Medical Group Stock Performance
NYSE MD opened at $23.45 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 11.38 and a beta of 0.70. The company's fifty day moving average is $21.49 and its two-hundred day moving average is $21.56. Pediatrix Medical Group, Inc. has a 52-week low of $11.84 and a 52-week high of $24.99.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $476.20 million for the quarter, compared to analyst estimates of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The business's quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $0.33 EPS. Equities research analysts forecast that Pediatrix Medical Group, Inc. will post 2.07 EPS for the current year.
Hedge Funds Weigh In On Pediatrix Medical Group
Institutional investors have recently added to or reduced their stakes in the company. Phocas Financial Corp. lifted its holdings in Pediatrix Medical Group by 44.5% during the 4th quarter. Phocas Financial Corp. now owns 335,551 shares of the company's stock valued at $7,177,000 after purchasing an additional 103,328 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Pediatrix Medical Group during the 3rd quarter valued at about $513,000. Allianz Asset Management GmbH lifted its holdings in Pediatrix Medical Group by 158.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 158,777 shares of the company's stock valued at $2,660,000 after purchasing an additional 97,365 shares during the last quarter. Dana Investment Advisors Inc. lifted its holdings in Pediatrix Medical Group by 5.6% during the 3rd quarter. Dana Investment Advisors Inc. now owns 801,462 shares of the company's stock valued at $13,424,000 after purchasing an additional 42,162 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in Pediatrix Medical Group during the 4th quarter valued at about $13,613,000. 97.71% of the stock is owned by institutional investors.
Analyst Ratings Changes
MD has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Jefferies Financial Group reiterated a "buy" rating and set a $27.00 target price on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Mizuho set a $24.00 target price on shares of Pediatrix Medical Group in a research report on Friday, May 8th. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a "hold" rating in a research report on Monday, April 13th. Finally, Zacks Research lowered shares of Pediatrix Medical Group from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, Pediatrix Medical Group presently has an average rating of "Hold" and a consensus price target of $22.50.
Check Out Our Latest Stock Report on Pediatrix Medical Group
About Pediatrix Medical Group
(
Get Free Report)
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
